[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352391-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-352391-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","baicalein-inhibits-the-progression-of-thyroid-cancer-by-suppressing-the-tpl2mek2erk2-pathway","Baicalein inhibits the progression of thyroid cancer by suppressing the TPL2/MEK2/ERK2 pathway","","Papillary thyroid cancer remains clinically challenging due to recurrent infections, metastasis, and complex underlying biology. This original research investigates baicalein’s anti-tumor effect against PTC through transcriptomic profiling, molecular docking, and pathway-focused mechanistic analysis. PLAU is identified as an up-regulated differentially expressed gene linked to tumor progression and metastasis, while BA modulates PLAU expression and suppresses the downstream TPL2/MEK2/ERK2 signaling axis. Findings support BA as a promising therapeutic strategy for PTC.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/baicalein-inhibits-the-progression-of-thyroid-cancer-by-suppressing-the-tpl2mek2erk2-pathway/352391/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/baicalein-inhibits-the-progression-of-thyroid-cancer-by-suppressing-the-tpl2mek2erk2-pathway/352391.png","ImageObject",300,407,{"name":42,"@type":43},"Liam","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-14","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of the study on baicalein and PTC?","Question",{"text":63,"@type":64},"To explore whether baicalein inhibits papillary thyroid cancer by modulating Golgi apparatus reprogramming via PLAU and by suppressing the TPL2/MEK2/ERK2 pathway.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were molecular targets and mechanisms investigated?",{"text":68,"@type":64},"The study used transcriptomic analysis to assess gene expression profiles and molecular docking to identify potential BA targets supporting the proposed mechanism.",{"name":70,"@type":61,"acceptedAnswer":71},"What role does PLAU play in the findings?",{"text":72,"@type":64},"PLAU is an up-regulated differentially expressed gene implicated in tumor development, lymph node metastasis, and immune cell infiltration; BA upregulates PLAU gene expression but PLAU protein is then inhibited through interaction that suppresses downstream pathways.",{"name":74,"@type":61,"acceptedAnswer":75},"Why do the authors conclude baicalein may be promising for PTC therapy?",{"text":76,"@type":64},"The results indicate baicalein suppresses key pathway signaling and influences PLAU-associated processes linked to progression and metastasis, supporting its potential as a therapeutic strategy.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},352391,1790125859,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,115,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},7,"Healthcare",40,"healthcare",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":117,"slug":118},8,30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":116,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":144,"language":145,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":146,"faqs":147,"seo_title":148,"seo_description":12,"update_tm":149,"read_time":150,"preview_page_count":33,"preview_urls":151},8796095461564,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Original Research PUBLISHED 28 January 2026  \nDOI 10.3389/fendo.2026.1739944  \nOPEN ACCESS  \nEDITED BY  \nParaskevi Xekouki,  \nUniversity of Crete, Greece  \nREVIEWED BY  \nXuzhu Gao,  \nSecond People’s Hospital of Lianyungang, China  \nMuhammad Sulaiman Saeed,  \nKhwaja Fareed University of Engineering and Information Technology (KFUEIT), Pakistan  \n*CORRESPONDENCE  \nShijian Yi  \n [yishijian1969@szu.edu.cn](yishijian1969@szu.edu.cn)  \nRECEIVED 06 November 2025  \nREVISED 27 December 2025  \nACCEPTED 05 January 2026  \nPUBLISHED 28 January 2026  \nCITATION  \nWu N, Wu Y, Zhang Q, Naeem M, Jing R, Luo Y-b and Yi S (2026) Baicalein inhibits the progression of thyroid cancer by suppressing the TPL2/MEK2/ERK2 pathway.  \nFront. Endocrinol. 17:1739944 .  \ndoi: 10.3389/fendo.2026.1739944  \nCOPYRIGHT  \n© 2026 Wu, Wu, Zhang, Naeem, Jing, Luo and Yi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nBaicalein inhibits the progression of thyroid cancer by suppressing the TPL2/MEK2/ERK2 pathway  \nNan Wu1, Yang Wu1, Qian Zhang2, Muhammad Naeem 1, Ren Jing1, Yuan-bin Luo 1 and Shijian Yi 1*  \n1 Department of Breast and Thyroid Surgery, South China Hospital, Medical School, Shenzhen University, Shenzhen, China, 2 Respiratory Medicine, Shenzhen Pingle Orthopedic Hospital, Shenzhen, China  \nIntroduction: Papillary thyroid cancer (PTC) is the most common type of endocrine malignancy caused by genetic mutations, hormonal imbalances, and environmental factors. However, recurrent infections, and metastasis in PTC patients remain challenged due to complexity of traditional methods. Baicalein (BA) is a kind of natural ﬂavonoid that exhibits the anti-cancer, anti-inﬂammatory, anti-tumor, and anti-viral activities. The molecular mechanism of baicalein in pathogenesis of PTC remains unclear. This study was designed to explore the inhibitory effects of BA against PTC by mediating the Golgi apparatus reprogramming via PLAU and suppressing the TPL2/MEK2/ERK2 pathway. Methods: Transcriptomic analysis was performed to explore the gene expression proﬁles. Molecular docking was employed to identify the potential targets to elucidate the molecular mechanism of action of BA.  \nResults: PLAU, an up-regulated DEG, is implicated in tumor development, lymph node metastasis, and inﬁltration levels of neutrophils and dendritic cells in thyroid cancer patients. Molecular docking analysis revealed that serum levels of uPA protein encoded by PLAU and Plau mRNA were elevated in PTC patients with metastasis and BRAF mutation. BA treatment upregulates PLAU gene expression, but this increased PLAU protein subsequently interacts with and inhibited by BA, leading to downstream pathway suppression.  \nConclusion: It was concluded it could be served as a promising therapeutic strategy for the treatment of PTC.  \nKEYWORDS  \nbaicalein, Golgi apparatus, MAPK pathway, PLAU, PTC, thyroid cancer  \nFrontiers in Endocrinology 01 [frontiersin.org](frontiersin.org)  \nWu et al. 10.3389/fendo.2026.1739944  \nGRAPHICAL ABSTRACT  \nIntroduction  \nThyroid cancer is the type of malignant tumor in the endocrine system, ranking ninth cancer in the global incidence with mortality rate (1–3) . Papillary thyroid carcinoma (PTC) constitutes about 84% of all the thyroid cancer pathological types. PTC patients exhibited the poor survival rate due to distant metastasis, complicated diagnosis, recurrent infections, and poor clinical management. The recurrent laryngeal nerve paralysis (RLNP) resulting in high invasion rate (1, 4) . Current treatment options for papillary thyroid cancer are limited to surgery, targeted ","cbCaift01SF3tnm9","https://ap.wps.com/l/cbCaift01SF3tnm9","pdf",27477825,15,"English","# Introduction\n## Papillary thyroid cancer challenges and current treatments\n## Role of PLAU and signaling implications in PTC\n# Methods\n## Transcriptomic analysis\n## Molecular docking\n# Results\n## PLAU as an up-regulated DEG and clinical associations\n## BA interaction with PLAU and pathway suppression\n# Conclusion","[{\"question\":\"What is the main purpose of the study on baicalein and PTC?\",\"answer\":\"To explore whether baicalein inhibits papillary thyroid cancer by modulating Golgi apparatus reprogramming via PLAU and by suppressing the TPL2/MEK2/ERK2 pathway.\"},{\"question\":\"How were molecular targets and mechanisms investigated?\",\"answer\":\"The study used transcriptomic analysis to assess gene expression profiles and molecular docking to identify potential BA targets supporting the proposed mechanism.\"},{\"question\":\"What role does PLAU play in the findings?\",\"answer\":\"PLAU is an up-regulated differentially expressed gene implicated in tumor development, lymph node metastasis, and immune cell infiltration; BA upregulates PLAU gene expression but PLAU protein is then inhibited through interaction that suppresses downstream pathways.\"},{\"question\":\"Why do the authors conclude baicalein may be promising for PTC therapy?\",\"answer\":\"The results indicate baicalein suppresses key pathway signaling and influences PLAU-associated processes linked to progression and metastasis, supporting its potential as a therapeutic strategy.\"}]","Baicalein inhibits the progression of thyroid cancer by suppressing the TPL2/MEK2/ERK2 pathway | PDF",1790099334,38,[152,156,160,164],{"page_no":22,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a1961650dadf6fce75e44f6ae315daae.webp",983,1389,{"page_no":26,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7020d2e8e56e575836c1db858f7aea0f.webp",982,1388,{"page_no":30,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/af2527f9d830efb616c47fb87d6bcb35.webp",981,1386,{"page_no":33,"url":165,"width":166,"height":167},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/66987273d758f35cd7d6b9907ec5cbfc.webp",980,1385]